BioCryst Pharmaceuticals BCRX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total liabilities?
- BioCryst Pharmaceuticals (BCRX) reported total liabilities of $1.02B in Q1 2026.
- How has BioCryst Pharmaceuticals's total liabilities changed year-over-year?
- BioCryst Pharmaceuticals's total liabilities increased by 9.3% year-over-year, from $931.97M to $1.02B.
- What is the long-term trend for BioCryst Pharmaceuticals's total liabilities?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's total liabilities has grown at a -19.3% compound annual growth rate (CAGR), from $972.49M to $633.31M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.